Crossmark

Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes

Crossref DOI link: https://doi.org/10.1186/s40942-025-00629-w

Published Online: 2025-01-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cattaneo, Jennifer

Forte, Paolo

Forte, Giovanni

Eandi, Chiara M.
License Information

Text and Data Mining valid from 2025-01-09

Version of Record valid from 2025-01-09
More Information

Article History

Received: 8 October 2024

Accepted: 1 January 2025

First Online: 9 January 2025

Declarations

:

: This study protocol was reviewed and approved locally by the ethics committee of Canton Vaud (Switzerland) CERVD: 2017 − 00493. Written informed consent was obtained from all patients.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below